Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced it will deliver an oral presentation on its investigational TNX-801 vaccine platform and lead a working group session at the World Vaccine Congress Europe, taking place October 19-21, 2026, in Amsterdam, Netherlands. The presentation, scheduled for October 21 at 1:15 p.m. CEST, will address the safety and efficacy of TNX-801, a live, attenuated, minimally replicative horsepox virus-based vaccine platform being developed to protect against mpox and other infectious diseases. Tonix will also lead a working group session titled “Vectored Vaccine Platforms: From Design to Improving Efficacy” on October 20 at 11:30 a.m. CEST.
The significance of this announcement lies in the potential of TNX-801 to address a critical public health need. Mpox, formerly known as monkeypox, has emerged as a global health concern, with outbreaks occurring in various regions. Current vaccines have limitations, and a new platform could offer improved safety and efficacy. Tonix’s horsepox virus-based approach is designed to be minimally replicative, which may reduce side effects while still inducing a robust immune response. If successful, TNX-801 could become an important tool in preventing mpox and potentially other infectious diseases.
Moreover, the presentation at the World Vaccine Congress Europe provides Tonix with a platform to showcase its science to key stakeholders, including researchers, clinicians, and industry partners. The working group session further positions the company as a thought leader in vaccine development. This visibility could attract collaborations and accelerate the development timeline. For investors, the event serves as a reminder of Tonix’s broader pipeline beyond its commercial CNS products. The company’s immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection, demonstrate a commitment to addressing unmet medical needs.
Tonix’s commercial-stage status, with its flagship fibromyalgia treatment TONMYA(TM) and acute migraine products, provides a revenue base to support its research and development efforts. The advancement of TNX-801 into clinical trials will be a key milestone to watch. While the product candidate is investigational and its efficacy and safety have not been established, the upcoming presentation may reveal promising preclinical data that could pave the way for further studies.
For those interested in learning more, the full press release is available at https://ibn.fm/BHVjU. Additional news and updates about Tonix Pharmaceuticals can be found in the company’s newsroom at https://ibn.fm/TNXP. The announcement was disseminated through BioMedWire, a specialized communications platform focused on the biotechnology and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers a range of services including wire distribution through InvestorWire and editorial syndication to 5,000+ outlets. These platforms help ensure that important developments like this reach a wide audience of investors and industry professionals.
